Filing Flows › Viatris (VTRS) › Q3 2026
Viatris (VTRS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Viatris (VTRS) reported revenue of $3.7B for the third quarter 2026 (Q3 2026), -0.3% from a year earlier and -0.2% from the quarter before. Operating margin was 7.0%, net loss $325M (8.7% of revenue).
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7B | -0.2% | -0.3% |
| Operating profit | $262M | 42× | +46% |
| Net earnings | −$325M | — | — |
| Operating cash flow | $899M | +136% | +21% |
| Free cash flow | $814M | +147% | +24% |
What changed
Revenue was $3.7B in Q3 2026, roughly flat year over year and roughly flat from the previous quarter. Brands was the largest line at 66% of revenue. Influvac ® lost $0.03B year over year (down 28%), 335% of the total change.
Gross margin was 38.4%, up 1.9 points from Q3 2025. Operating profit was $0.26B, a 7.0% margin (up 2.2 points year over year). Operating expenses fell 1% while revenue was flat. The quarter ended with a net loss of $0.33B, wider than the previous quarter's $0.12B loss.
Operating cash flow was $0.90B (up 21% year over year). Non-cash charges added back $0.70B of depreciation and amortization and $0.04B of share-based compensation. Working capital and other items added $0.49B. Capital expenditures of $0.09B left free cash flow of $0.81B.
Questions
What was Viatris' revenue in the third quarter 2026?
Viatris (VTRS) reported revenue of $3.7B for the third quarter 2026 (Q3 2026), -0.3% from a year earlier and -0.2% from the quarter before.
Was Viatris profitable in the third quarter 2026?
Operating profit was $262M (7.0% of revenue) and net loss $325M.
Source: Viatris 10-Q on SEC EDGAR.